FDA panel backs birth control patch despite risks

By MATTHEW PERRONE , AP Health Writer

(AP) -- A panel of federal health advisers said Friday that a birth control patch from Johnson & Johnson probably carries a higher risk of blood clots than older drugs, but should remain available as an option for women who have trouble taking a daily pill.

The Food and Drug Administration's panel of reproductive health experts voted 19-5 that the benefits of the Ortho Evra patch outweigh its risks, specifically a potentially higher risk of dangerous blood clots in the legs and lungs. Panelists said the patch can be especially useful for younger women who have difficulty sticking to a daily pill regimen.

"I have many teenagers and it's the only method they'll use - for them it's the perfect method," said Dr. Melissa Gilliam of the University of Chicago. The FDA sought the experts' advice as it reviews the safety of newer hormone-based contraceptives launched in the past decade. The agency is not required to follow their advice, though it often does.

Johnson & Johnson's weekly Ortho Evra patch was approved in 2001 and has been marketed for its convenience as an "option for busy women who are looking to simplify life." The drug works about as well as other contraceptive medications, allowing about one unplanned pregnancy per year for every 100 women.

Studies assessing Ortho Evra's blood clot risk have reached differing conclusions over the years. At least two studies found that patch users have twice the risk of clots as women taking birth control pills. Even a slightly higher risk can be critical because blood clots can trigger heart attacks, strokes and blockages in lungs or blood vessels, which in rare cases have been fatal, even among young women.

The most recent study by the FDA found that women using the patch have a 50 percent higher risk of clots than women taking various oral contraceptives. However, agency scientists said the data was not definitive.

Panelists voted 20-3 with one abstention that the drug's current label is inadequate and should be updated with the latest information about the potentially higher risk. In discussion, a majority of panelists said Ortho Evra probably carries a higher risk than older birth control pills, though the risk is less clear when compared with newer birth control pills launched in the last decade.

Despite the safety concerns, the experts stressed that Ortho Evra fills a unique niche among birth control products.

"There is no alternative in this range for women who desire hormonal contraception but can't take the pill, so I think it is important to maintain that option," said Dr. Michele Orza of the George Washington University.

Prescriptions for Ortho Evra have declined steadily over the last five years, from 5 million in 2006 to about 1.3 million last year.

The decline has followed repeated updates by J&J of New Brunswick, N.J., to the product's labeling, including language indicating that patients absorb up to 60 percent more estrogen via the patch than with the pill.

"The company will continue to collaborate with the FDA on a product label that adequately reflects the known risks and benefits of the product, including new information," said Jeff Christensen, communications manager with J&J's Janssen unit.

Ortho Evra is part of a new generation of contraceptives that use recently-developed, laboratory-made forms of the female hormone progesterone. In the past decade the medications have overtaken older medications, though studies have reached conflicting conclusions on whether the drugs carry a higher risk of . On Thursday, the same panel recommended clearer risk labeling on Yaz, Yasmin and similar pills marketed by Bayer and Teva Pharmaceuticals. As with Ortho Evra, the panel affirmed their overall benefit of the pills for women.

Ortho Evra sales last year totaled $124 million, trailing Merck & Co. Inc.'s NuvaRing, which posted sales of $437 million, according to health care data firm IMS Health. NuvaRing is the most widely used, non-pill contraceptive drug.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

Some birth control shows higher clot risk: US

Oct 28, 2011

Some birth control products, including contraceptive pills, rings and patches for women, carry a significantly higher risk of blood clot than low-dose medications, US regulators said Thursday.

FDA revisits safety of newer birth control drugs

Dec 05, 2011

Birth control drugs that were heavily promoted as having fewer side effects and the ability to clear up acne and other hormonal bothers are under new scrutiny from safety regulators.

FDA ties newer birth control drugs to blood clots

Oct 27, 2011

(AP) -- Safety concerns with the popular birth control pill Yaz increased Thursday as federal health scientists reported that the Bayer drug and other newer birth control treatments appear to increase the risk of dangerous ...

FDA panel wants more risk information on Yaz pills

Dec 09, 2011

(AP) -- Federal health experts said Thursday that drug labeling for Yaz and other widely-used birth control pills should be updated to emphasize recent data suggesting a higher risk of blood clots with the drugs than older ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

7 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments